» Articles » PMID: 39344658

M6A Modification of RNA in Cervical Cancer: Role and Clinical Perspectives

Overview
Journal RNA Biol
Specialty Molecular Biology
Date 2024 Sep 30
PMID 39344658
Authors
Affiliations
Soon will be listed here.
Abstract

N6-methyladenosine (m6A) is widely recognized as the predominant form of RNA modification in higher organisms, with the capability to finely regulate RNA metabolism, thereby influencing a series of crucial physiological and pathological processes. These processes include regulation of gene expression, cell proliferation, invasion and metastasis, cell cycle control, programmed cell death, interactions within the tumour microenvironment, energy metabolism, and immune regulation. With advancing research into the mechanisms of RNA methylation, the pivotal role of m6A modification in the pathophysiology of reproductive system tumours, particularly cervical cancer, has been progressively unveiled. This discovery has opened new research avenues and presented significant potential for the diagnosis, prognostic evaluation, and treatment of diseases. This review delves deeply into the biological functions of m6A modification and its mechanisms of action in the onset and progression of cervical cancer. Furthermore, it explores the prospects of m6A modification in the precision diagnosis and treatment of cervical cancer, aiming to provide new perspectives and a theoretical basis for innovative and advanced treatment strategies for cervical cancer.

References
1.
Wu H, Dong H, Fu Y, Tang Y, Dai M, Chen Y . Expressions of m6A RNA methylation regulators and their clinical predictive value in cervical squamous cell carcinoma and endometrial adenocarcinoma. Clin Exp Pharmacol Physiol. 2020; 48(2):270-278. DOI: 10.1111/1440-1681.13412. View

2.
Yue Y, Liu J, Cui X, Cao J, Luo G, Zhang Z . VIRMA mediates preferential mA mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 2018; 4:10. PMC: 5826926. DOI: 10.1038/s41421-018-0019-0. View

3.
Zhang P, Tang Y, Zhao J, Yang J, Chen Y, Gong Y . TRIM11 regulated by m6A modification promotes the progression of cervical cancer by PHLPP1 ubiquitination. Neoplasma. 2023; 70(5):659-669. DOI: 10.4149/neo_2023_230104N7. View

4.
Wei J, Liu F, Lu Z, Fei Q, Ai Y, He P . Differential mA, mA, and mA Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm. Mol Cell. 2018; 71(6):973-985.e5. PMC: 6151148. DOI: 10.1016/j.molcel.2018.08.011. View

5.
Li N, Kang Y, Wang L, Huff S, Tang R, Hui H . ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci U S A. 2020; 117(33):20159-20170. PMC: 7443867. DOI: 10.1073/pnas.1918986117. View